DFV890: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 142 patientsc19early.org

DFV890 for COVID-19

Serious outcome risk
DFV890
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−3%
Mortality (1)−3%
RCTs (1)−3%
Late (1)−3%
00.511.5+
← DFV890
reduces riskIncreased
risk →
c19early.org
October 2026

DFV890 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.59death8/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.598/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.59death8/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Madurka (RCT)−1%1.01 · 0.74–1.38no recov.70 (n)72 (n)
Late treatment−1%1.01 · 0.74–1.3870 (n)72 (n)1% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.95
All studies−1%1.01 · 0.74–1.3870 (n)72 (n)1% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9500.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.59death8/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.598/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →
c19early.org
October 2026

DFV890 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Madurka (RCT)−3%1.03 · 0.41–2.59death8/708/72
Late treatment−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.96
All studies−3%1.03 · 0.41–2.598/708/723% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9600.511.52+
Rotate screen for more detailsIncrease width for more details
← DFV890
reduces riskDFV890
increases risk →